Skip to main content
Erschienen in: Tumor Biology 5/2010

01.10.2010 | Research Article

Synthesis and structural characterization of the peptide epitope of the ovarian cancer biomarker CA125 (MUC16)

verfasst von: Zach T. Berman, Lee J. Moore, Kathleen E. Knudson, Rebecca J. Whelan

Erschienen in: Tumor Biology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

A highly conserved region of 21 amino acids flanked by cysteine residues, contained within a larger repeated domain, has been proposed to be the antibody-binding site in the ovarian cancer biomarker CA125 (MUC16). In this study solid-phase peptide synthesis with Fmoc protection chemistry was used to assemble a 21-mer peptide corresponding to the most frequently occurring antibody binding sequence in CA125. Potentially significant sequence variants were also synthesized. Peptide secondary structure was investigated using Fourier transform infrared spectroscopy, revealing the consensus sequence peptide to be largely unstructured at physiological pH whether the cysteine residues were reduced or were oxidized to form an intramolecular disulfide bond. Substitution of serine for proline at position 8 (P8S) results in β-sheet formation in peptides involved in intramolecular disulfide bonds. This β-sheet structure does not persist in peptides incapable of intramolecular disulfide bonding because of sequence nor in peptides treated with the reducing agent dithiothreitol. In CA125, P8S is predicted to occur in ∼25% of repeat domains, suggesting that this structural motif is a non-negligible contributor to overall structure and function. These findings suggest that future structural characterization efforts of CA125 should be especially mindful of the amino acid sequence and oxidation state of the protein.
Literatur
2.
Zurück zum Zitat Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–7.CrossRefPubMed Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–7.CrossRefPubMed
3.
Zurück zum Zitat Bast RC, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7.CrossRefPubMed Bast RC, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7.CrossRefPubMed
4.
Zurück zum Zitat Bast RC. Status of tumor markers in ovarian cancer screening. J Clin Oncol. 2003;21:200s–5s.CrossRefPubMed Bast RC. Status of tumor markers in ovarian cancer screening. J Clin Oncol. 2003;21:200s–5s.CrossRefPubMed
5.
Zurück zum Zitat Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival—a review of the epidemiological literature. J Ovarian Res. 2009;2:13.CrossRefPubMed Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival—a review of the epidemiological literature. J Ovarian Res. 2009;2:13.CrossRefPubMed
6.
Zurück zum Zitat Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15 suppl 3:274–81.CrossRefPubMed Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15 suppl 3:274–81.CrossRefPubMed
7.
Zurück zum Zitat Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol. 2007;107:526–31.CrossRefPubMed Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol. 2007;107:526–31.CrossRefPubMed
8.
Zurück zum Zitat O’Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumor Biol. 2001;22:348–66.CrossRef O’Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumor Biol. 2001;22:348–66.CrossRef
9.
Zurück zum Zitat Yin BWT, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001;276:27371–5.CrossRefPubMed Yin BWT, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001;276:27371–5.CrossRefPubMed
10.
Zurück zum Zitat O’Brien TJ, Beard JB, Underwood LJ, Shigemasa K. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumor Biol. 2002;23:154–69.CrossRef O’Brien TJ, Beard JB, Underwood LJ, Shigemasa K. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumor Biol. 2002;23:154–69.CrossRef
11.
Zurück zum Zitat Yin BWT, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer. 2002;98:737–40.CrossRefPubMed Yin BWT, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer. 2002;98:737–40.CrossRefPubMed
12.
Zurück zum Zitat Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70:431–57.CrossRefPubMed Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70:431–57.CrossRefPubMed
13.
Zurück zum Zitat Singh AP, Senapati S, Ponnusamy MP, Jain M, Lele SM, Davis JS, et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 2008;9:1076–85.CrossRefPubMed Singh AP, Senapati S, Ponnusamy MP, Jain M, Lele SM, Davis JS, et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 2008;9:1076–85.CrossRefPubMed
14.
Zurück zum Zitat Imai S, Haga S, Kiyozuka Y. Epitope characterization of MUC1 antibodies. Tumor Biol. 1998;19 suppl 1:30–4.CrossRef Imai S, Haga S, Kiyozuka Y. Epitope characterization of MUC1 antibodies. Tumor Biol. 1998;19 suppl 1:30–4.CrossRef
15.
Zurück zum Zitat Schol DJ, Meulenbroek MFA, Snijdewint FGM, von Mensdorff-Pouilly S, Verstraeten RA, Murakami F, et al. “Epitope fingerprinting” using overlapping 20-mer peptides of the MUC1 tandem repeat sequence. Tumor Biol. 1998;19 suppl 1:35–45.CrossRef Schol DJ, Meulenbroek MFA, Snijdewint FGM, von Mensdorff-Pouilly S, Verstraeten RA, Murakami F, et al. “Epitope fingerprinting” using overlapping 20-mer peptides of the MUC1 tandem repeat sequence. Tumor Biol. 1998;19 suppl 1:35–45.CrossRef
16.
Zurück zum Zitat Grinstead JS, Koganty RR, Krantz MJ, Longenecker BM, Campbell AP. Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide–antibody interactions. Biochem. 2002;41:9946–61.CrossRef Grinstead JS, Koganty RR, Krantz MJ, Longenecker BM, Campbell AP. Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide–antibody interactions. Biochem. 2002;41:9946–61.CrossRef
17.
Zurück zum Zitat Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res. 1993;53:5386–94.PubMed Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res. 1993;53:5386–94.PubMed
18.
Zurück zum Zitat Ferreira CSM, Matthews CS, Missailidis S. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumor Biol. 2006;27:289–301.CrossRef Ferreira CSM, Matthews CS, Missailidis S. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumor Biol. 2006;27:289–301.CrossRef
19.
Zurück zum Zitat Warren DJ, Nustad K, Beard JB, O’Brien TJ. Expression and epitope characterization of a recombinant CA 125 repeat: fourth report from the ISOBM TD-1 workshop. Tumor Biol. 2009;30:51–60.CrossRef Warren DJ, Nustad K, Beard JB, O’Brien TJ. Expression and epitope characterization of a recombinant CA 125 repeat: fourth report from the ISOBM TD-1 workshop. Tumor Biol. 2009;30:51–60.CrossRef
20.
Zurück zum Zitat Chan WC, White PD, editors. Fmoc solid phase peptide synthesis: a practical approach. New York: Oxford University Press; 2000. Chan WC, White PD, editors. Fmoc solid phase peptide synthesis: a practical approach. New York: Oxford University Press; 2000.
21.
Zurück zum Zitat Diem M. Introduction to modern vibrational spectroscopy. New York: John Wiley and Sons; 1993. Diem M. Introduction to modern vibrational spectroscopy. New York: John Wiley and Sons; 1993.
22.
Zurück zum Zitat Barth A, Zscherp C. What vibrations tell us about proteins. Q Rev Biophys. 2002;35:369–430.CrossRefPubMed Barth A, Zscherp C. What vibrations tell us about proteins. Q Rev Biophys. 2002;35:369–430.CrossRefPubMed
23.
Zurück zum Zitat Maeda T, Inoue M, Koshiba S, Yabuki T, Aoki M, Nunokawa E, et al. Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16). J Biol Chem. 2004;279:13174–82.CrossRefPubMed Maeda T, Inoue M, Koshiba S, Yabuki T, Aoki M, Nunokawa E, et al. Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16). J Biol Chem. 2004;279:13174–82.CrossRefPubMed
24.
Zurück zum Zitat Gubbels JAA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high-affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5:50.CrossRefPubMed Gubbels JAA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high-affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5:50.CrossRefPubMed
25.
Zurück zum Zitat Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, et al. A binding domain on mesothelein for CA125/MUC16. J Biol Chem. 2009;284:3739–49.CrossRefPubMed Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, et al. A binding domain on mesothelein for CA125/MUC16. J Biol Chem. 2009;284:3739–49.CrossRefPubMed
26.
Zurück zum Zitat Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007;67:4924–32.CrossRefPubMed Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007;67:4924–32.CrossRefPubMed
Metadaten
Titel
Synthesis and structural characterization of the peptide epitope of the ovarian cancer biomarker CA125 (MUC16)
verfasst von
Zach T. Berman
Lee J. Moore
Kathleen E. Knudson
Rebecca J. Whelan
Publikationsdatum
01.10.2010
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2010
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0062-4

Weitere Artikel der Ausgabe 5/2010

Tumor Biology 5/2010 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.